Institute of Hepatobiliary Surgery and Southwest Cancer Center, Southwest Hospital, Third Military Medical University, Chongqing, China.
World J Surg. 2013 Jan;37(1):192-201. doi: 10.1007/s00268-012-1781-z.
Liver resection offers a chance of cure for patients with hepatocellular carcinoma (HCC). Hepatic pedicle clamping (HPC) is commonly used to reduce blood loss during hepatectomy. Hepatic ischemia-reperfusion (I/R) injury has recently been reported to be a major factor in accelerated tumor growth. We therefore evaluated the effect of intermittent HPC on the prognosis of patients after liver resection.
The clinicopathological features and serum/tissue samples of 386 HCC patients who underwent curative liver resection were prospectively collected. The patients were divided into the HPC group (over 30 min) and the non-HPC group. Disease-free survival and overall survival were analyzed using multivariate analyses, Kaplan-Meier curves, and log-rank tests. Matrix metalloproteinases and E-selectin were measured to study hepatic I/R injury.
The preoperative clinicopathological data were comparable between the HPC group (n = 224) and the non-HPC group (n = 162). During the study period, 257 of the 386 patients (66.6 %) developed tumor recurrence. The overall tumor recurrence and intrahepatic tumor recurrence rates were not significantly different between the two groups. There were no significant differences between the two groups with respect to the 1-, 3-, and 5-year disease-free and overall survival rates. Similarly, subgroup analyses also showed no marked difference in survival rates for patients with cirrhosis in the two groups. The levels of mRNA in liver tissues and serum concentrations of MMP-2, MMP-9, and E-selectin showed no significant differences between the pre- and post-occlusion periods.
Intermittent HPC produced no adverse effect on disease-free and overall survival for patients who underwent liver resection for HCC.
肝切除术为肝细胞癌(HCC)患者提供了治愈的机会。肝蒂阻断(HPC)常用于减少肝切除术中的失血。最近有报道称,肝缺血再灌注(I/R)损伤是加速肿瘤生长的一个主要因素。因此,我们评估了间歇性 HPC 对肝切除术后患者预后的影响。
前瞻性收集了 386 例接受根治性肝切除术的 HCC 患者的临床病理特征和血清/组织样本。患者分为 HPC 组(超过 30 分钟)和非 HPC 组。使用多变量分析、Kaplan-Meier 曲线和对数秩检验分析无病生存率和总生存率。测量基质金属蛋白酶和 E-选择素以研究肝 I/R 损伤。
HPC 组(n=224)和非 HPC 组(n=162)的术前临床病理数据相当。在研究期间,386 例患者中有 257 例(66.6%)发生肿瘤复发。两组患者的总肿瘤复发率和肝内肿瘤复发率无显著差异。两组患者的 1 年、3 年和 5 年无病生存率和总生存率均无显著差异。同样,亚组分析也显示两组肝硬化患者的生存率无明显差异。肝组织中 mRNA 的水平和 MMP-2、MMP-9 和 E-选择素的血清浓度在阻断前后均无显著差异。
间歇性 HPC 对接受 HCC 肝切除术的患者的无病生存率和总生存率没有不良影响。